WO2009066468A1 - 微粒子状の医療用材料及びその使用 - Google Patents

微粒子状の医療用材料及びその使用 Download PDF

Info

Publication number
WO2009066468A1
WO2009066468A1 PCT/JP2008/003432 JP2008003432W WO2009066468A1 WO 2009066468 A1 WO2009066468 A1 WO 2009066468A1 JP 2008003432 W JP2008003432 W JP 2008003432W WO 2009066468 A1 WO2009066468 A1 WO 2009066468A1
Authority
WO
WIPO (PCT)
Prior art keywords
particulate
cell
drug
stem cells
carried
Prior art date
Application number
PCT/JP2008/003432
Other languages
English (en)
French (fr)
Inventor
Masayuki Ishihara
Shingo Nakamura
Satoko Kishimoto
Yasuhiro Kanatani
Hidemi Hattori
Masaki Nambu
Hirofumi Yura
Original Assignee
Masayuki Ishihara
Shingo Nakamura
Satoko Kishimoto
Yasuhiro Kanatani
Hidemi Hattori
Masaki Nambu
Hirofumi Yura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2007301245A external-priority patent/JP2011026202A/ja
Priority claimed from JP2008147231A external-priority patent/JP2011024423A/ja
Application filed by Masayuki Ishihara, Shingo Nakamura, Satoko Kishimoto, Yasuhiro Kanatani, Hidemi Hattori, Masaki Nambu, Hirofumi Yura filed Critical Masayuki Ishihara
Publication of WO2009066468A1 publication Critical patent/WO2009066468A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　本発明は、低分子ヘパリンとプロタミンとから構成される平均粒径が１０μｍ未満の微粒子を提供する。本発明の微粒子は、注射器やカテーテルなどを介する投与に適しており、ＦＧＦ－２等の薬物を安定に担持し、目的部位で担持した薬物を徐放できるドラッグデリバリー用薬物包接担体として使用できる。本発明の微粒子は、担持した細胞を安定に保持し生存させながら体内に注入できる細胞担体として使用でき、再生医療における細胞移植に適している。また、本発明の微粒子は細胞培養基板の被覆材として使用でき、当該微粒子で表面を被覆した基板上では、従来は十分な収率が得られにくかったＣＤ-３４陽性造血系幹細胞や間葉系幹細胞の、無血清又は低濃度血清での培養が可能となる。
PCT/JP2008/003432 2007-11-21 2008-11-21 微粒子状の医療用材料及びその使用 WO2009066468A1 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007301245A JP2011026202A (ja) 2007-11-21 2007-11-21 徐放性薬物包接担体及びそれを含む医薬組成物
JP2007-301245 2007-11-21
JP2008147231A JP2011024423A (ja) 2008-06-04 2008-06-04 微粒子細胞担体及びそれを含む細胞導入システム及び細胞培養システム
JP2008-147231 2008-06-04
US10894808P 2008-10-28 2008-10-28
US61/108,948 2008-10-28

Publications (1)

Publication Number Publication Date
WO2009066468A1 true WO2009066468A1 (ja) 2009-05-28

Family

ID=40667300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003432 WO2009066468A1 (ja) 2007-11-21 2008-11-21 微粒子状の医療用材料及びその使用

Country Status (1)

Country Link
WO (1) WO2009066468A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011108517A1 (ja) * 2010-03-01 2011-09-09 富士フイルム株式会社 生体親和性を有する高分子ブロックと細胞からなる細胞構造体
JP2014012114A (ja) * 2011-08-31 2014-01-23 Fujifilm Corp 細胞移植用細胞構造体および細胞移植用細胞集合体
JP2015134193A (ja) * 2011-08-31 2015-07-27 富士フイルム株式会社 細胞移植用細胞構造体および細胞移植用細胞集合体
JP2016136848A (ja) * 2015-01-26 2016-08-04 富士フイルム株式会社 薬剤の評価方法及び薬剤スクリーニング方法
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHIZUKO ONO ET AL.: "Fragmin/Protamine Micro Carrier ni yoru FGF-2 no Kassei Hogo Koka to Kekkan Shinsei Koka", NATIONAL DEFENSE MEDICAL JOURNAL, vol. 54, no. 10, October 2007 (2007-10-01), pages 259 - 267 *
HIDEKI KOBAYASHI ET AL.: "Teibunshi Heparin Kassei ni Taisuru Protamine Chuwa Koka", KIDNEY, vol. 15, no. 5, 1993, pages 226 - 230 *
PARK, Y-J. ET AL.: "ATTEMPTS: a heparin/ protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects", ADVANCED DRUG DELIVERY, vol. 55, 2003, pages 251 - 265 *
SATOKO KISHIMOTO ET AL.: "Enkisei Sen'iga Saibo Zoshoku Inshi o Mochiita Kekkan Shinsei Ryoho no Tameno Shinki Yakuzai Carrier no Kaihatsu", JAPANESE SOCIETY OF VETERIANY SCIENCE GAKUJUTSU SHUKAI KOEN YOSHISHU, vol. 145TH, 7 March 2008 (2008-03-07), pages 226 *
SATOKO KISHIMOTO ET AL.: "Fragmin/Protamine Biryushi Hifuku Kishitsu o Mochiita Kanyokei Oyobi Zoketsukei Kansaibo no Sentakuteki Zoshoku", THE JAPANESE SOCIETY OF CARBOHYDRATE RESEARCH NENKAI YOSHISHU, vol. 28TH, 29 July 2008 (2008-07-29), pages 147 *
SATOKO KISHIMOTO ET AL.: "Fragmin/Protamine Micro Carrier ni yoru Shibo Soshiki Yurai Kanyokei Saibo no Gishu to Kekkan Shinsei Koka", THE JAPANESE SOCIETY FOR WOUND HEALING PROGRAM- SHOROKUSHU, vol. 37TH, December 2007 (2007-12-01), pages 76 *
SATOKO KISHIMOTO ET AL.: "Fragmin/Protamine Micro Ryushi Hifuku Plate o Mochiita Kotsuzui Saibo Yurai Kanyokei Kansaibo Oyobi Zoketsukei Kansaibo no Sentakuteki Zoshoku Baiyo ni Kansuru Kisoteki Kento", JAPANESE SOCIETY FOR MEDICAL AND BIOLOGICAL ENGINEERING PROGRAM. RONBUNSHU, vol. 47TH, 8 May 2008 (2008-05-08), pages S3 - 7-10 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011108517A1 (ja) * 2010-03-01 2011-09-09 富士フイルム株式会社 生体親和性を有する高分子ブロックと細胞からなる細胞構造体
CN102858381A (zh) * 2010-03-01 2013-01-02 富士胶片株式会社 包括具有生物相容性的聚合物块和细胞的细胞构建体
JPWO2011108517A1 (ja) * 2010-03-01 2013-06-27 富士フイルム株式会社 生体親和性を有する高分子ブロックと細胞からなる細胞構造体
KR101744040B1 (ko) 2010-03-01 2017-06-07 후지필름 가부시키가이샤 생체 친화성을 갖는 고분자 블록과 세포로 이루어지는 세포 구조체
US9597432B2 (en) 2010-03-01 2017-03-21 Fujifilm Corporation Cell construct comprising polymer blocks having biocompatibility and cells
JP5762399B2 (ja) * 2010-03-01 2015-08-12 富士フイルム株式会社 生体親和性を有する高分子ブロックと細胞からなる細胞構造体
US9211266B2 (en) 2011-08-31 2015-12-15 Fujifilm Corporation Cell construct for cell transplantation and cell aggregate for cell transplantation
JP2015134193A (ja) * 2011-08-31 2015-07-27 富士フイルム株式会社 細胞移植用細胞構造体および細胞移植用細胞集合体
JP2014012114A (ja) * 2011-08-31 2014-01-23 Fujifilm Corp 細胞移植用細胞構造体および細胞移植用細胞集合体
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10590380B2 (en) 2012-07-24 2020-03-17 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US11371013B2 (en) 2012-07-24 2022-06-28 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
JP2016136848A (ja) * 2015-01-26 2016-08-04 富士フイルム株式会社 薬剤の評価方法及び薬剤スクリーニング方法

Similar Documents

Publication Publication Date Title
WO2009066468A1 (ja) 微粒子状の医療用材料及びその使用
Yasa et al. 3D‐Printed microrobotic transporters with recapitulated stem cell niche for programmable and active cell delivery
Li et al. How to improve the survival of transplanted mesenchymal stem cell in ischemic heart?
US11781114B2 (en) Materials and methods for expansion of stem cells
Kouroupis et al. Increased mesenchymal stem cell functionalization in three-dimensional manufacturing settings for enhanced therapeutic applications
Liu et al. Metabolic regulation of mesenchymal stem cell in expansion and therapeutic application
Liu et al. Dual suppression effect of magnetic induction heating and microencapsulation on ice crystallization enables low-cryoprotectant vitrification of stem cell–alginate hydrogel constructs
Li et al. A PNIPAAm-based thermosensitive hydrogel containing SWCNTs for stem cell transplantation in myocardial repair
Tongers et al. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges
Kavanagh et al. Mesenchymal stem cell priming: fine-tuning adhesion and function
Forte et al. Updates on the hematologic tumor microenvironment and its therapeutic targeting
US20190119649A1 (en) Methods for generating augmented stem cell-derived beta cells and uses thereof
Liu et al. Spheroid formation and enhanced cardiomyogenic potential of adipose-derived stem cells grown on chitosan
Hassink et al. Stem cell therapy for ischemic heart disease
Rosca et al. Emerging role of stem cells-derived exosomes as valuable tools for cardiovascular therapy
Lewis et al. Macrophages as a cell-based therapy for liver disease
Zhou et al. Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium
Jadczyk et al. Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology
Behbahan et al. Bone marrow therapies for chronic heart disease
Zhang et al. Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model
Park et al. In situ formation of proangiogenic mesenchymal stem cell spheroids in hyaluronic acid/alginate core–shell microcapsules
JP2011024423A (ja) 微粒子細胞担体及びそれを含む細胞導入システム及び細胞培養システム
Yu et al. Optimal stem cell transporting conditions to maintain cell viability and characteristics
Kir et al. What is the status of regenerative therapy in heart failure?
Masterson et al. The role of cells and their products in respiratory drug delivery: the past, present, and future

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08851755

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08851755

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP